Dave Muoio
Dr. Yuri Maricich, chief medical officer at Pear Therapeutics, speaks on his company's experience bringing a digital therapeutic product through the regulator's experimental program for health software.
Somryst, a prescription digital therapeutic combining cognitive behavioral therapy and personalized sleep restriction, is the first software product to put the FDA's early Precertification Program framework through its paces.
The Auto Ejection Fraction Tool and the Auto Bladder Volume Tool both employed AI to help Butterfly iQ users more easily evaluate the patient's condition.
The Series A raise comes just a few months after the company raised $3 million in seed funding.
Also: Healthcare analytics company Apixio picks up a new VP of solutions; Eagle Telemedicine hires on a healthcare-system vet as SVP of operations.
A weekend update to the virtual assistant includes a new COVID-19 conversation tree, which relies on information and guidance from the CDC and links users to consumer telehealth services if appropriate.
Nurx, Carbon Health and Everlywell have officially halted their mail-order testing-kit services. But at least one startup is still moving to secure an Emergency Use Authorization for its at-home rapid serology diagnostic.
The temporary policy also extends to some clinical decision support software used in conjuction with these remote monitor devices.
[Since this article was published, the FDA has released an alert warning that it has not yet authorized any COVID-19 home testing kits]
Early data from the roughly 100,000-participant effort suggest infrequent social distancing and regional behavior disparities (as of March 15).